MBX Biosciences, Inc.
MBX
$10.73
$0.242.29%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | ||
|---|---|---|---|---|---|
| Net Income | -76.25% | -78.51% | -108.43% | -107.38% | |
| Total Depreciation and Amortization | 41.46% | 87.50% | 61.54% | 29.73% | |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | |
| Total Other Non-Cash Items | -76.95% | 4.46% | 487.21% | 2,962.50% | |
| Change in Net Operating Assets | 78.05% | 54.63% | 1,879.41% | 91.19% | |
| Cash from Operations | -43.88% | -89.80% | -79.79% | -87.07% | |
| Capital Expenditure | -67.27% | -159.09% | -1,358.06% | -1,200.00% | |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | |
| Cash Acquisitions | -- | -- | -- | -- | |
| Divestitures | -- | -- | -- | -- | |
| Other Investing Activities | -132.71% | -442.06% | -137.20% | 573.67% | |
| Cash from Investing | -132.59% | -441.73% | -139.52% | 562.50% | |
| Total Debt Issued | -- | -- | -- | -- | |
| Total Debt Repaid | -- | -- | -- | -- | |
| Issuance of Common Stock | 926.32% | 1,026,435.29% | -92.11% | 173.91% | |
| Repurchase of Common Stock | -- | -- | -- | -- | |
| Issuance of Preferred Stock | -- | -7.31% | -- | -- | |
| Repurchase of Preferred Stock | -- | -- | -- | -- | |
| Total Dividends Paid | -- | -- | -- | -- | |
| Other Financing Activities | -- | -7,223.33% | -- | -- | |
| Cash from Financing | -794.74% | 244.27% | -377.76% | 165.22% | |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | |
| Net Change in Cash | -108.36% | 185.45% | -273.36% | 154.52% | |